MedTrace Logo

Metabolic Effects of Switching Kaletra to Boosted Reyataz

NCT00413153 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-03-09

Study results available
· View outcomes & findings →

Summary

To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.

Conditions

  • HIV Infections

Interventions

DRUG

atazanavir/ritonavir

atazanavir 300mg + ritonavir 100mg once daily

DRUG

lopinavir/ritonavir

patient remains on their pre-study dose of lopinavir/ritonavir

Sponsors & Collaborators

Principal Investigators

  • Steven K Grinspoon, MD · MGH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413153 on ClinicalTrials.gov